|
Allele Symbol Allele Name Allele ID |
Tg(Krt1-15-cre/PGR*)22Cot transgene insertion 22, George Cotsarelis MGI:3511785 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
14 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• following transgene activation and Pou5f1 recombination in 8-week old mice, hair follicles display normal differentiated cell types and sebaceous glands; wound healing is normal in mutant mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• during wound regeneration, RU486-treated mice exhibit YFP+ cells in the suprabasal layers but not the basal layers unlike in control mice
|
|
• in RU486-treated mice
|
|
• following treatment with RU486, plated YFP+ hair follicle stem cells do not exhibit spreading unlike YFP- cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• when induction is performed from P20-27, upper hair follicles and sebaceous glands are intact
• hyperproliferation is not observed in the epidermis
|
|
• after treatment of skin with RU486 to induce cre deletion, external hair growth fails
|
|
• when induction is performed from P20-27, secondary hair germ cells in some mutant hair follicles appear abnormal or absent at P60
|
|
• when animals are treated topically with RU486 for 5 days prior to hair plucking at P54, hair follicles in treated areas do not progress through anagen, while controls show robust hair regrowth 14 days after plucking
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• all mice develop skin tumors four months after RU846 induction
|
|
• after RU846 induction
|
|
• after RU846 induction
|
|
• all mice develop skin tumors four months after RU846 induction
|
|
• after RU846 induction
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice rapidly develop skin tumors beginning 1 month after induction with topical application of RU486 to the back of the skin with 100% penetrance
|
|
• tumors that develop after RU486 induction are well-to-moderately differentiated squamous cell carcinomas with an epidermal lineage or basaloid squamous cell carcinomas of unknown stem cell origin
|
|
• a subset of benign or locally invasive tumors form adjacent to the squamous cell carcinoma precursor lesions, which are of hair follicle (trichoepitheliomas, basaloid squamous cell carcinoma) or sebaceous gland origin (sebaceous adenomas) after induction with topical application of RU486
|
|
• metastases develop between 8 and 18 weeks after induction with RU486, with 28% of tumor-bearing mice developing lung metastasis and 1 of 18 mice showing lymph node metastasis
|
|
• a subset of benign or locally invasive tumors form adjacent to the squamous cell carcinoma precursor lesions, which are of hair follicle (trichoepitheliomas, basaloid squamous cell carcinoma) or sebaceous gland origin (sebaceous adenomas) after induction with topical application of RU486
|
|
• a few benign papillomas are seen after induction with topical application of RU486
|
|
• mice rapidly develop skin tumors beginning 1 month after induction with topical application of RU486 to the back of the skin with 100% penetrance
|
|
• tumors that develop after RU486 induction are well-to-moderately differentiated squamous cell carcinomas with an epidermal lineage or basaloid squamous cell carcinomas of unknown stem cell origin
|
|
• a subset of benign or locally invasive tumors form adjacent to the squamous cell carcinoma precursor lesions, which are of hair follicle (trichoepitheliomas, basaloid squamous cell carcinoma) or sebaceous gland origin (sebaceous adenomas) after induction with topical application of RU486
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| squamous cell carcinoma | DOID:1749 | J:203922 | ||
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop benign papillomas without progressing to malignancy following topical application of RU486 to the back of skin at 3 weeks of age for 5 days
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 2-4 months following RU486 treatment, tumors develop in the face in 35% of treated mutants
|
|
• 2-4 months following RU486 treatment, lip tumors develop in 57% of treated mice
|
|
• 2-4 months following RU486 treatment, tumors develop in the back skin in 14% of treated mice
|
|
• skin tumors are benign papillomas with no sign of malignant transformtion seen up to 4 months after treatment with RU486
• double mutants not treated with tamoxifen develop some papillomas but with increased latency (>6 months)
|
|
• 2-4 months following RU486 treatment, tumors develop in the back skin in 14% of treated mice
|
|
• skin tumors are benign papillomas with no sign of malignant transformtion seen up to 4 months after treatment with RU486
• double mutants not treated with tamoxifen develop some papillomas but with increased latency (>6 months)
|
|
• 2-4 months following RU486 treatment, tumors develop in the face in 35% of treated mutants
|
|
• 2-4 months following RU486 treatment, lip tumors develop in 57% of treated mice
|
|
• 2-4 months following RU486 treatment, tumors develop in the face in 35% of treated mutants
|
|
• 2-4 months following RU486 treatment, lip tumors develop in 57% of treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• increased interstitial inflammation
|
|
• starting around 3 months and associated with increased hair loss
|
|
• remaining hair becomes matted
|
|
• dystrophic hair follicles
• strands of fibrous connective tissue run perpendicular to the epidermis from dystrophic hair follicles
|
|
• follicular ostia are dilated and plugged
|
|
• sometimes dystrophic and contiguous with follicular plugs
|
|
• becomes flaky and crusty
|
|
• mild
|
|
• perifollicular fibrosis
|
|
• associated with progressive hair loss
|
|
• increased interstitial inflammation
|
|
• sometimes dystrophic and contiguous with follicular plugs
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following topical application of RU486 to the back of the skin at 3 weeks of age for 5 days
|
|
• following topical application of RU486 to the back of the skin at 3 weeks of age for 5 days
|
|
• mice initially develop hair loss following topical application of RU486 to the back of the skin at 3 weeks of age for 5 days
|
|
• degenerated hair follicles are seen following topical application of RU486 to the back of the skin at 3 weeks of age for 5 days
|
| N |
• induction with RU486 does not result in development of spontaneous skin tumors
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• following wounding, mice show no differences in the recruitment of epidermal melanocytes to the wound area relative to control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• after RU486 treatment, mice exhibit no defects in coat/hair pigmentation at 2nd telogen relative to control mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• hyperproliferation is not observed in the epidermis with RU486 treatment from P20-P27
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice treated with RU486 prior to diphtheria toxin injection exhibit reduced proliferation and atrophy in the esophageal epithelia compared with wild-type mice
|
|
• mice treated with RU486 prior to diphtheria toxin injection exhibit reduced proliferation and atrophy in the esophageal epithelia compared with wild-type mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools